METHYLATION OF SRD5A2 PROMOTER PREDICTS A BETTER OUTCOME FOR PATIENTS UNDERGOING ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER

被引：0
|
作者：
Deng, Tuo
Lin, Xueming
Wu, Shulin
Zhang, Zhenwei
Wu, Chin-Lee
Yan, Liying
Taplin, Mary-Ellen
Wang, Zongwei
Olumi, Aria
机构：
来源：
JOURNAL OF UROLOGY | 2019年 / 201卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP81-16
引用
收藏
页码：E1178 / E1179
页数：2
相关论文
共 50 条
  • [21] Patients with rapid decreasing of prostate-specific antigen in the initial androgen deprivation therapy are more likely to progress to castration-resistant prostate cancer
    Ji, G.
    INTERNATIONAL JOURNAL OF UROLOGY, 2017, 24 : 101 - 101
  • [22] Role of Androgen Deprivation Treatment in Patients With Castration-Resistant Prostate Cancer, Receiving Docetaxel-Based Chemotherapy
    Lee, Jae-Lyun
    Kim, Jeong Eun
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Lee, Junghsin
    Kim, Choung-Soo
    Hong, Jun Hyuk
    Hong, Bumsik
    Song, Cheryn
    Ahn, Hanjong
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 140 - 144
  • [23] Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy
    Kang, Minyong
    Lee, Sangchul
    Oh, Jong Jin
    Hong, Sung Kyu
    Lee, Sang Eun
    Byun, Seok-Soo
    PROSTATE INTERNATIONAL, 2015, 3 (04) : 123 - 126
  • [24] Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide
    Rathkopf, D. E.
    Smith, M. R.
    Ryan, C. J.
    Berry, W. R.
    Shore, N. D.
    Liu, G.
    Higano, C. S.
    Alumkal, J. J.
    Hauke, R.
    Tutrone, R. F.
    Saleh, M.
    Maneval, E. Chow
    Thomas, S.
    Ricci, D. S.
    Yu, M. K.
    de Boer, C. J.
    Trinh, A.
    Kheoh, T.
    Bandekar, R.
    Scher, H. I.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2017, 28 (09) : 2264 - 2271
  • [25] Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer
    Saad, Fred
    Fizazi, Karim
    UROLOGY, 2015, 86 (05) : 852 - 861
  • [26] Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer
    Antonarakis, Emmanuel S.
    Lu, Changxue
    Wang, Hao
    Luber, Brandon
    Nakazawa, Mary
    Roeser, Jeffrey C.
    Chen, Yan
    Fedor, Helen L.
    Lotan, Tamara L.
    De Marzo, Angelo M.
    Isaacs, John T.
    Isaacs, William B.
    Nadal, Rosa
    Paller, Channing J.
    Denmeade, Samuel R.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Luo, Jun
    CANCER RESEARCH, 2014, 74 (19)
  • [27] Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
    Jang, Ho Seong
    Koo, Kyo Chul
    Cho, Kang Su
    Chung, Byung Ha
    YONSEI MEDICAL JOURNAL, 2016, 57 (05) : 1070 - 1078
  • [28] RISK STRATIFICATION DETERMINED BY DURATION OF ANDROGEN DEPRIVATION THERAPY, SERUM ALKALINE PHOSPHATASE, AND HEMOGLOBIN LEVEL PREDICTS OVERALL SURVIVAL IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Uchimoto, Taizo
    Komura, Kazumasa
    Inamoto, Teruo
    Azuma, Haruhito
    JOURNAL OF UROLOGY, 2020, 203 : E953 - E953
  • [29] Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy
    Lu, Hsi-Huei
    Chiu, Nan-Tsing
    Tsai, Mu-Hung
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (07) : 508 - 515
  • [30] Influence of Statins on Survival Outcome in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Inhibitors
    Henriquez Lopez, I.
    Gomez, J.
    Torres, L.
    Acosta, J.
    Arquez, M.
    LaFuerza, A.
    Martinez, F.
    Miranda, M.
    Arenas, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E278 - E279
12345